Emodin Inhibits Colorectal Tumorigenesis and Ameliorates Toxicity Associated With Chemotherapy


Reference #: 01294

The University of South Carolina is offering licensing opportunities for Emodin Inhibits Colorectal Tumorigenesis and Ameliorates Toxicity Associated with Chemotherapy


Colorectal cancer is one of the most common malignancies, accounting for approximately 1.36 million new cases worldwide annually. It is the third most common cancer diagnosed in both men and women in the United States. It is estimated that 95,520 new cases of colon cancer will be diagnosed in 2017 in the US alone. Overall, the lifetime risk of developing colorectal cancer is about 1 in 21 (4.7%) for men and 1 in 23 (4.4%) for women. Approximately 50% of stage II patients and 75% of stage III and IV colorectal cancer patients receive chemotherapy.

Invention Description:

We have found that a natural compound found in various Chinese medicinal herbs, can significantly reduce colorectal cancer. When the compound was administered with chemotherapy, we found that it significantly reduced the toxicity that is characteristic of chemotherapy agents.

Potential Applications:

1) Colon cancer therapy

2) Complementary agent to be used to increase efficacy and decrease toxicity of chemotherapy

Advantages and Benefits:

Further, the compound prevented the body weight loss associated with chemotherapy treatment, increased survival, and offset the chemotherapy induced sensitivity to pain and fatigability.

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Emodin for Use in Gastrointestinal Cancer Therapy Utility United States 16/398,471   4/30/2019     Published
For Information, Contact:
Technology Commercialization
University of South Carolina
Daping Fan
Angela Murphy
© 2024. All Rights Reserved. Powered by Inteum